Statin Initiation Guided by Lipoprotein(a) and Comprehensive Cardiovascular Risk Assessment

Guideline Foundations

Required Elements Before Starting a Statin

When Elevated Lipoprotein(a) Influences Statin Decisions

Primary‑Prevention Scenarios

Use of Coronary Calcium Scoring to Resolve Uncertainty

Practical Clinical Algorithm (AHA/ACC & Canadian Recommendations)

ESC/EAS Perspective (European Guidelines)

Pharmacologic Effects on Lipoprotein(a) Levels

Statin Therapy

• The American College of Cardiology notes that statin therapy (and low‑fat diets) can paradoxically increase Lipoprotein(a) concentrations in some patients, although this rise does not offset the overall cardiovascular benefit of statins. 9

PCSK9‑Inhibitor Therapy

• According to the American College of Cardiology, PCSK9‑inhibitor agents (evolocumab, alirocumab) lower low‑density lipoprotein cholesterol by approximately 50 %–60 % and reduce Lipoprotein(a) levels by about 20 %–30 % in patients with elevated Lp(a). 9